13 market-changing drugs are expected to hit the European market this year and these blockbusters re...
Read moreSince 29 July 2016 NICE) has employed a new fast-track appraisal process for oncology drugs.
Read moreNHS England’s cost-effectiveness watchdog, (NICE), issued a first draft document saying that it di...
Read moreThe new NICE oncology appraisal process aims to enable fast-track appraisals, allowing earlier acces...
Read moreEarlier this year, the UK government announced support for three new specialist centres capable of c...
Read moreSince 29th July 2016 the NICE appraisal process for oncology indications in England has been modifie...
Read moreIn June 2018, Remap Consulting had the pleasure of attending the annual National Institute of Health...
Read moreTo determine if there is a difference between incremental cost-effectiveness ratios (ICERs) in oncol...
Read moreIn the current climate of tighter budgetary controls and greater price scrutiny, a uniform pricing s...
Read moreThis study investigates NICE evaluations of new cancer indications and legacy CDF indications (not p...
Read more